Optimal treatment duration of neoadjuvant endocrine therapy in women aged 60 years or older with estrogen receptor-positive, HER2-negative invasive breast cancer.

CONCLUSIONS: Neoadjuvant exemestane therapy is an effective strategy in older women with hormone-sensitive breast cancer. PMID: 33250473 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/33250473?dopt=Abstract

Source: Journal of Nippon Medical School - November 30, 2020 Category: Universities & Medical Training Authors: Hayashi Y, Takei H, Saito T, Kai T, Inoue K, Kurosumi M, Ninomiya J, Saitama Breast Cancer Clinical Study Group (SBCCSG) Tags: J Nippon Med Sch Source Type: research